Jfl Life SciencesShare price, financial results, shareholding and management
- Market cap
- ₹39 cr
- Stock P/E
- 6.1peers 21.3
- Book value
- ₹13.9
- Price to book
- 0.85
- EV / operating profit
- 5.1
- Market cap to sales
- 0.30
- ROCE · FY26
- 18.2%
- ROE · FY26
- 15.0%
- ROE, 3-year average
- 11.6%
- Operating margin · FY26
- 8.9%peers 12.7%
- Sales growth, 3 years
- 45.1%
- Profit growth, 3 years
- 28.7%
- Debt to equity
- 0.47peers 0.57
- Borrowings
- ₹21.7 cr
- Interest cover
- 5.1×
- Cash from business / op. profit
- -37%
- Debtor days
- 148
- Pledged
- 0.00%
- Promoter holding
- 67.47%
- Change in promoter holding
- 0.00 pts
- Shareholders
- 904
- 52-week high / low
- ₹15 / ₹9
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
newboard is reading this company's filings. Its plain description, key points, management and study will appear here soon; the figures below are worked out from what it has filed.
Jfl Life Sciences share price chart
Close on 6 Nov 2026 · +4.89% on the day · Vol 36,000
Daily prices to 6 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 6 Nov 2026
- 1 month
- +15.1%
- 3 months
- -13.6%
- 6 months
- +27.6%
- 1 year
- -9.2%
- Traded a day, 20 days
- ₹0.02 cr
- Taken for delivery
- 91%
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +60% | +54% |
| 3 years, a year | +45% | +29% |
Jfl Life Sciences revenue and profit growth
Half-yearly results · Profit and lossSales have grown fast. Last year profit grew more slowly than sales, so the profit kept from each rupee of sales slipped.
SME companies report every six months.
Jfl Life Sciences half-yearly results
SME companies report every six months · ₹ crore
| H2FY25 | |
|---|---|
| Sales | 32.99 |
| Expenses | 30.25 |
| Operating profit | 2.74 |
| OPM | 8.3% |
| Interest | 0.55 |
| Depreciation | 0.51 |
| Profit before tax | 1.68 |
| Net profit | 0.80 |
Jfl Life Sciences profit and loss
Full years to March, FY19 to FY26 · ₹ crore, consolidated where reported
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 32 | 30 | 33 | 34 | 43 | 47 | 82.04 | 131.38 |
| Expenses | 30 | 28 | 31 | 28 | 39 | 42 | 73.84 | 119.67 |
| Operating profit | 1 | 2 | 2 | 5 | 4 | 5 | 8.20 | 11.71 |
| OPM | 4.2% | 6.0% | 7.0% | 16.0% | 9.0% | 10.0% | 10.0% | 8.9% |
| Other income | 0 | 0 | 0 | 1 | 2 | 1 | 0.01 | 0.07 |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1.08 | 2.11 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0.99 | 1.08 |
| Exceptional and other items | · | -1 | · | · | -1 | -1 | · | · |
| Profit before tax | 0 | 0 | 1 | 4 | 4 | 4 | 6.14 | 8.60 |
| Tax rate | 28.0% | 29.0% | 0.0% | 25.0% | 25.0% | 25.0% | 32.2% | 25.6% |
| Net profit | 0 | 0 | 1 | 3 | 3 | 3 | 4.16 | 6.40 |
| EPS ₹ | 1.25 | 1.50 | 1.50 | 0.59 | 0.43 | 0.50 | 1.26 | 1.94 |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 8.0% | 0.0% | 0.0% |
The years to FY24 come rounded to the nearest crore in the source.
Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.
Jfl Life Sciences profitability
Margins and returns on capitalLast year the company kept about as much from each rupee of sales as the year before. It earns a moderate return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|
| Operating margin | 4.2% | 6.0% | 7.0% | 16.0% | 9.0% | 10.0% | 10.0% | 8.9% |
| Tax rate | 28.0% | 29.0% | 0.0% | 25.0% | 25.0% | 25.0% | 32.2% | 25.6% |
| ROCE | · | 7.2% | 10.5% | 23.8% | 15.2% | 12.3% | 15.7% | 18.2% |
| ROE | · | 0.0% | 16.8% | 34.3% | 14.0% | 8.8% | 11.0% | 15.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 8.0% | 0.0% | 0.0% |
Jfl Life Sciences debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown. It borrowed much more last year. Its loans are smaller than its own money. Last year the business used more cash than it brought in. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers pay faster than they did in FY24, which frees up the company's money.
Bars below the line are cash going out.
Jfl Life Sciences balance sheet
At each 31 March · ₹ crore
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0.42 | 0.42 | 0.50 | 8 | 11 | 11 | 33 | 33 |
| Reserves | 5 | 5 | 6 | 3 | 21 | 25 | 6.46 | 12.87 |
| Net worth | 5.42 | 5.42 | 6.50 | 11 | 32 | 36 | 39.46 | 45.87 |
| Borrowings | 8 | 9 | 17 | 16 | 7 | 6 | 10.59 | 21.73 |
| Other liabilities | 2.58 | 9.58 | 5.50 | 21 | 10 | 15 | 21.86 | 38.65 |
| Total liabilities | 16 | 24 | 29 | 48 | 49 | 57 | 71.91 | 106.25 |
| Fixed assets | 2 | 5 | 6 | 7 | 7 | 12 | 12.24 | 14.54 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 14 | 19 | 23 | 41 | 42 | 45 | 59.67 | 91.71 |
| Receivables | · | · | · | · | · | · | 34.95 | 53.26 |
| Inventory | · | · | · | · | · | · | 23.24 | 34.55 |
| Cash | · | · | · | · | · | · | 0.06 | 1.46 |
| Trade payables | · | · | · | · | · | · | 17.76 | 29.28 |
Jfl Life Sciences cash flow
₹ crore
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -3 | 3 | -6 | 2 | -9 | 8 | -3.53 | -4.34 |
| Cash from investing | -1 | -3 | -2 | -1 | 1 | -6 | -0.01 | -3.94 |
| Cash from financing | 4 | 0 | 7 | -1 | 8 | -2 | 3.54 | 9.10 |
| Net cash flow | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0.82 |
| Capital spending | · | · | · | · | · | · | 0.40 | 3.38 |
Working capital
Days
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 111 | 153 | 132 | 215 | 192 | 197 | 155 | 148 |
| Inventory days | 21 | 52 | 72 | 212 | 130 | 149 | 128 | 110 |
| Days payable | 18 | 122 | 58 | 218 | 76 | 92 | 98 | 93 |
| Cash conversion cycle | 115 | 83 | 146 | 208 | 246 | 254 | 186 | 165 |
| Working capital days | 62 | 7 | 74 | 117 | 221 | 181 | 124 | 103 |
Jfl Life Sciences peers and competitors
Listed SME companies in the same industryBy sales, Jfl Life Sciences is number 9 of the 34 listed SME companies in pharmaceuticals & biotechnology.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Zenith Drugs | 68 | 17.2 | 171 | 3.9 | 7.1% | 0.75 |
| Mono Pharmacare | 16 | 44.6 | 166 | 0.4 | 2.4% | 1.79 |
| Astonea Labs | 341 | 68.1 | 148 | 5 | 9.0% | 0.74 |
| Influx Healthtech | 632 | 30.8 | 147 | 20.5 | 20.3% | 0.00 |
| Jfl Life Sciences | 39 | 6.1 | 131 | 6.4 | 8.9% | 0.47 |
| Dipna Pharmachem | 11 | 3.5 | 129 | 3 | 3.9% | 0.21 |
| Trident Lifeline | 481 | 25.3 | 129 | 19 | 22.0% | 0.73 |
| Chandra Bhagat Pharma | 32 | 10.5 | 116 | 3 | 3.3% | 0.50 |
| Quest Laboratories | 154 | 10.3 | 112 | 15 | 16.3% | 0.08 |
| KRM Ayurveda | 573 | 28.6 | 102 | 20 | 30.0% | 0.00 |
| Sotac Pharmaceuticals | 100 | 17.3 | 101 | 5.8 | 17.7% | 0.64 |
| Median of the 10 others | 127 | 21.3 | 129 | 5.4 | 12.7% | 0.57 |
Jfl Life Sciences shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company. Big foreign and Indian funds own very little. The number of shareholders is about the same.
Jfl Life Sciences shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Sep 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 | |
|---|---|---|---|---|---|---|---|---|
| Promoters | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% |
| Foreign investors (FIIs) | - | 0.00% | - | - | - | - | - | - |
| Indian institutions (DIIs) | - | 0.00% | - | - | - | - | - | - |
| HNIs (over ₹2 lakh each) | - | 3.16% | 10.67% | 10.64% | 10.41% | 10.43% | 10.47% | 11.43% |
| Small holders (up to ₹2 lakh) | - | 25.60% | 18.28% | 18.24% | 18.13% | 18.06% | 17.84% | 16.99% |
| Companies and others | - | 3.77% | 3.58% | 3.65% | 3.99% | 4.04% | 4.22% | 4.11% |
| Number of shareholders | 966 | 997 | 1,008 | 998 | 991 | 971 | 943 | 904 |
The named holders are at 30 Sept 2026, beside 30 June 2026, each under the group the pattern files them in.
Jfl Life Sciences latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- Shareholding, 30 Sept 2026: promoters unchanged at 67.47%.
Jfl Life Sciences announcements
21 on record, latest first; each opens the filing on the exchange
- Certificate under SEBI (Depositories and Participants) Regulations, 2018For the quarter ended September 30, 2026PDF ↗
- Trading WindowClosure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015PDF ↗
- AppointmentOf Mrs BHAVNA SHAH ID Reappointment as Independent Director of the company w.e.f. February 10, 2027PDF ↗
- AppointmentOf Mr SONU JAIN Reappointment ID as Independent Director of the company w.e.f. January 18, 2027PDF ↗
- AppointmentOf Mrs Tejal Smiral Patel WTD Reappointment as Executive Director of the company w.e.f. January 18, 2027PDF ↗
- AppointmentOf Mr Mr. Smiral Ashwinkumar Patel (Re-Appointment ) as Managing Director of the company w.e.f. January 18, 2027PDF ↗
- General UpdatesGeneral UpdatesPDF ↗
- Shareholders meetingSrutinizers report of Annual General Meeting held on August 25, 2026. Further, the company has informed the Exchange regarding voting resultsPDF ↗
- Shareholders meetingProceedings of Annual General Meeting held on August 25, 2026PDF ↗
- Copy of Newspaper PublicationCopy of Newspaper PublicationPDF ↗
- Outcome of Board Meeting, the financial results for the period ended Jun 30, 2026PDF ↗
- Copy of Newspaper PublicationNewspaper Publication of Notice for Shareholder s Meeting 25th august,2026PDF ↗
Jfl Life Sciences annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
Jfl Life Sciences share split, bonus and dividends
From the corporate actions the company announces on the exchange
- Rights issueRIGHTS 1:1 @ PREMIUM RS 0/-ex-date 10 March 2026
- Bonus issueBONUS 2:1ex-date 24 Sept 2024
- DividendDIVIDEND - RE 0.25 PER SHAREex-date 13 Sept 2024
Checks we ran on Jfl Life Sciences' data · 10
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- !The two halves of FY26 as reported add up to sales of ₹104.55 cr, the full year to ₹131.38 cr; one of the filings may have been restated.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (3,29,95,323 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- !The two half-years of FY26 add up to ₹104.5 cr of sales against ₹131.4 cr for the full year, so the half-years of FY26 are held back.
- !Earnings per share changes basis between FY21 (₹1.50) and FY22 (₹0.59) because the share count behind it changes; EPS is shown as reported, and growth is worked out on profit.
- ✓Revenue and profit are reported for every year shown, FY19 to FY26.
- iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.
Questions people ask about Jfl Life Sciences
What does Jfl Life Sciences do?
Jfl Life Sciences is an SME company listed on NSE Emerge, in pharmaceuticals & biotechnology.
What is the share price of Jfl Life Sciences?
₹11.8 at the close on 6 Nov 2026, from the exchange's daily figures.
What is the market cap of Jfl Life Sciences?
₹39 cr at the close on 6 Nov 2026, on 3,29,95,323 shares.
What is the P/E of Jfl Life Sciences?
6.1 times FY26 profit at the close on 6 Nov 2026 (our arithmetic).
What are Jfl Life Sciences' revenue and profit?
Revenue ₹131 cr and profit after tax ₹6 cr in FY26.
Who are the promoters of Jfl Life Sciences?
The promoter group; promoters held 67.47% at 30 Sept 2026.
What is Jfl Life Sciences' website?
www.jfllifesciences.com
More SME companies like Jfl Life Sciences
Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.
- Medicamen OrganicsMEDIORG · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2024Market cap ₹35 cr
- Chandra Bhagat PharmaCBPL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹50 cr
- Goldline PharmaceuticalGLPL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹28 cr
- Onyx BiotecONYX · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2024Market cap ₹68 cr
- Zenith DrugsZENITHDRUG · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2024Market cap ₹72 cr
- Shelter PharmaSHELTER · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹75 cr
Every listed SME company in Pharmaceuticals & Biotechnology → · SME companies listed in 2022 →
Built from 21 exchange announcements, 8 shareholding patterns and 8 years of reported results. Every figure carries its source; where the documents are silent, the page says so.